Introduction
In patients with chronic obstructive pulmonary diseases with hypoxemia, long-term oxygen therapy (LTOT) is an already documented therapy that shows definite survival benefit. Two major randomized studies published in the early 1980s, which include the study carried by British Medical Research Council [1] and the Nocturnal Oxygen Therapy Trial study [2] , found that patients on LTOT for at least 15 h/day had improved survival benefit [1, 2] . Patients with COPD with hypoxemia are known to complain of increased pulmonary hypertension, impaired quality of life, and different degrees of functional disability [3] . LTOT improves neuropsychological function and reduces pulmonary hypertension. However, there is no clear idea about how LTOT can affect quality of life [4] . LTOT could lead to improvement in exercise capacity, fatigue, sleep quality, the need for hospitalization, and the frequency of COPD exacerbations, but only a few studies have examined how LTOT could improve the quality of life, and results are conflicting [5, 6] . Although patients nowadays differ from the patient included in these studies, at least in terms of multiple comorbidities, the recent guidelines are mainly dependent on the previously mentioned two major studies for prescription of LTOT [7] . In the present study, we focused on studying the effect of LTOT in patients with COPD with severe hypoxemia regarding mortality and frequency of exacerbation, quality of life, and pulmonary function tests (PFTs).
Patients and methods
This prospective observational study was done in the period from October 2015 to October 2016 on 50 patients with stable COPD of stages III and IV diagnosed according to Global Initiative for Chronic Obstructive Lung Disease (GOLD 2015) [8] guidelines from Chest Department, Assuit University Hospital. LTOT was prescribed for patients according to the criteria of British thoracic society (BTS) guidelines [9] by using a continous flow oxygen concentrator. Two patients were noncompliant during the follow-up, so the actual number of studied patients who continued till the end of the study was 48 patients.
Exclusion criteria
The exclusion criteria were as follows:
(1) Patients with extrapulmonary causes of respiratory failure and pulmonary causes other than COPD. (2) Patients who started LTOT before the beginning of the study.
We obtained an informed written consent from each patient, and the study was approved by Faculty of Medicine Ethics Committee.
Patients were all prescribed the medications for COPD according to the GOLD 2015 [8] guidelines to reach the maximum improvement before prescription of LTOT.
All selected patients in the study were subjected to history taking, including demographic data, medical history, and clinical examination.
Prescription of LTOT was done at the time of discharge after end of exacerbation, and the amount of liters was prescribed to reach oxygen saturation of more than 92% with either the 5-l or the 8-l device.
Spirometry (FVC%, FEV1%, FEV1/FVC) was done for patients with COPD at the time of discharge to reach a proper staging and at 3 and 6 months during follow-up. The test was done in pulmonary function unit in the chest department of Assuit University Hospital by experienced healthcare providers using ZAN300, MGA, USB,CO, CH4 analyzer, SN:9303004 (Oberthulba, Germany). Testing was performed according to recommendations of American Thoracic Society [3] . Six-minute walking test (6MWT) was done where each patient was instructed to walk as far as possible during a 6-min period over a 30m course in a corridor according to ATS standards. Oxygen saturation was measured on the room air before and after the test.
In this study, we used the St George's Respiratory Questionnaire (SGRQ) to measures quality of life in patients with COPD (translated form). It is divided to three parts: part I explores the symptoms score, and parts 2 and 3 the activity and effect scores. Finally, a total score is then calculated. Before and at 3 and 6 months after using LTOT, the patient was asked to reply to the questionnaire [6] . The answer for each question has a score between zero and 100. The final score equals 100 multiplied by the summed scores of the positive answers for each component in the questionnaire.
A sample of arterial blood gases (ABG) was taken on prescription of LTOT after end of exacerbation and before discharge from the hospital and then at 3-and 6-month follow-up. Samples were taken on the room air and analyzed in ABG unit of Assuit university hospital by ABG analyzer (GEM Premier 4000, BEDFORT, USA) with calculation of PaSO 2 , SaO 2 , and PaCO 2 .
The patients were asked about the adherence to LTOT regarding flow and number of hours according to physician's instructions.
Data concerning the concentrator itself, including common failure modes, replacement parts needed, equipment downtime, and repair costs, were also collected, along with complications including fire or explosions.
Statistical analysis of data
The IBM SPSS Statistics software package verson 16 was used in the data analysis. Descriptive statistics were done in the form of frequencies and mean±SD, and then analytical statistics were done such as χ 2 , independent sample t-test, correlations, and regression tests. Paired t-test is used to compare numerical parametric data before and after prescription of LTOT. Values were considered significant when P values were equal or less than 0.05.
Results
Clinical characteristics of the studied patient are displayed in Table 1 . Improvement of BMI after the use of LTOT among patients of COPD is illustrated in ( Table 2) . Improvement in oxygen tension and oxygen saturation after the use of LTOT in patients with COPD is shown in Table 3 . Table 4 shows the oxygen saturation (SO 2 ) during 6MWT without oxygen after the use of LTOT. Improvement in all components of the SGRQ is observed in Table 5 . Table 6 illustrates the survival outcome of the patients after 1-year follow-up on long-term oxygen therapy. Table 7 displays the reduction in the rate of exacerbation and hospitalization.
PFT did not show difference regarding forced expiratory volume in the first second (FEV 1 ) as well as forced vital capacity values (FVC) on the3-and 6month follow-up.
More than half of the patients were adherent to the use of LTOT (66.7%) more than 10 h daily (all night and the rest divided all over the day); moreover, periodic maintenance was done by only half the patients included in the study, and no complications were recorded.
Discussion
The use of LTOT in a group of patients with COPD with severe hypoxemia is mandatory as COPD is not a curable disease and maximum benefits of other modalities of treatment are limited. Therefore, research studies have continued on the use of LTOT, which improved patients' health after therapy. In this study, 48 patients with COPD on LTOT were observed regarding improvement of quality of life, ABG, adherence to oxygen therapy, number of hospitalization, BMI, PFT, and survival.
The present study was in agreement with Okubadejo et al. [10] and Eaton et al. [11] regarding the role of LTOT in improvement of quality of life. Okubadejo et al. [10] agreed that LTOT using a continuous flow oxygen concentrator does not affect quality of life adversely and concluded that patients receiving LTOT showed slightly improvement in their quality of life compared with the control group with no oxygen therapy.
The study by Okubadejo The improvement of quality of life could be owing to the improvement of hypoxemia and its harmful effect on different body organs [12] .
This might explains why defective memory is highly prevalent in patients with hypoxemic COPD [13] , which has a negative effect on daily activities and the sensation of disability in these patients. In accordance with this study is the study done by Heaton et al. [14] that divided the study group into continuous oxygen therapy or nocturnal oxygen treatment and followed them up for 6 months. Improved survival and better neuropsychological performance were found in the continuous oxygen group. The study concluded that LTOT especially continuous oxygen definitely improves brain functioning among patients with COPD with severe hypoxemia as well as survival.
Regarding exercise tolerance and endurance, while observing oxygen saturation during 6MWT, we found significant improvement on 6-month followup. This is in line with Haidl et al. [15] who studied 28 inpatients of a German hospital who had an acute exacerbation of COPD, mild hypoxemia (PaO 2 : 66.5 mmHg) and moderate reversible hypercapnia during exercise. Patients were randomized to LTOT or to a control group. The control group received no oxygen therapy. The study showed that increased endurance time in patients with COPD with mild to moderate hypoxemia was reduced with the use of LTOT.
Moreover, these results agreed with Dean et al. [16] who reported that supplemental O 2 improved dyspnea and exercise tolerance in patients with COPD and mild hypoxemia at rest. This could be explained by that supplemental oxygen reduces minute ventilation and the work of breathing by improving both the respiratory muscle functional capacities as well as the diaphragmatic muscle capacity; moreover, oxygen delays the onset of respiratory-muscle fatigue [16] . Regarding ABG, the current study showed significant improvement in oxygen tension and oxygen saturation on oxygen withdrawal test on 3-and 6-month followup, which is aligned with Ersson et al. [17] . The present study showed some variation in that no patient could dispense LTOT despite significant improvement of oxygen tension and oxygen saturation on room air, whereas in the study by Erssons [17] on follow-up after 3 months, 12 patients of 17 could dispense oxygen therapy. This might reflect that the decision concerning LTOT was taken much earlier in the study by Errsons [17] which may be related to the availability of resources, whereas in this study, scarce resource requires meticulous selection of cases for LTOT and prescription for only advanced cases with more severe irreversible hypoxemia. Improvement in oxygen tension and saturation may be explained by the improvement of pulmonary hemodynamic and reduction of cardiac work as a result of supplemental oxygen [18] .
In the current study, patients showed poor compliance on LTOT. Only 24% of patients showed adherence to LTOT for 15 h or more. Walshaw et al. [19] studied 67 patients who received LTOT by oxygen concentrators and found that only 55% were following the physician prescription for the use of oxygen therapy. Moreover, in the UK, Howard et al. [20] evaluated 531 LTOT patients who were prescribed oxygen concentrators, and found that 50% of the patients were not using the equipment at the level required for a clinical benefit to be expected. Pépin et al. [21] studied 930 patients who used LTOT in France and found that only 45% could achieve therapy for 15 h or more per day. This was justified in the last study by the shortage of the physician's instructions to use oxygen therapy for 15 h or more per day as well as cessation of smoking, use of oxygen in all domestic situations and absence of adverse effects from oxygen treatment.
In the current study, 30% of the patients were using LTOT 10 h/day, which is in agreement with Shiner and colleagues who evaluated 63 patients using LTOT and found that only 33% used LTOT in the required range (12-24 h/day).
Kampelmacher et al. [22] investigated the compliance of patients prescribed LTOT. Twenty-percent of their studied patients used oxygen less than prescribed owing to multiple reasons; the most important of which were treatment difficulties, lack of breathlessness, fear of oxygen addiction, and feeling ashamed of therapy.
In this study after the use of LTOT, a significant reduction in number of hospitalization by 60% was found compared with the preoxygen period. This is comparable with the findings of previous studies [23, 24] where there was statistically significant reductions in number of hospitalization of 40-50%.
Regarding the severity of COPD, the patients in this study seem to be similar to those studied previously as FEV 1 %, PaO 2 %, and hospitalizations per patient per year were comparable.
According to the study by Silverman et al. [25] , the most common causes of hospitalization in patients receiving LTOT are heart failure, exacerbations of COPD, and lung infections. In hypoxemic patients, the effect of oxygen therapy on hospitalization could be owing to alleviating the severe desaturations attacks and stabilizing pulmonary hemodynamics [26] .
Regarding survival on home oxygen therapy, overall, crude survival was 86% at 1-year follow-up in this study. Six patients (four males and two females) of 48 patient at the beginning of the study died during the observation period, which is aligned with the two previous randomized controlled trials: Nocturnal Oxygen Therapy Trial [2] and British Medical Research Council [1] .
This study runs against the recent Long-Term Oxygen Treatment Trial (LOTT study), which found that long-term oxygen therapy for patients with COPD did not prolong survival. However, the LOTT study dealt with patients with only mild to moderate hypoxemia (pO 2 : 66.5±6.3 mmHg) and not patients with severe hypoxemia (pO 2 : 48.56±3.98 mmHg) as in our study [27] .
On patients follow-up regarding PFT, there was no statistical significance change regarding FEV 1, FVC, and FEV 1 /FVC during the studied period which is compatible with the study by Okubadejo et al. [26] .
Limitation of this study is that we did not classify patients according to the presence of comorbidities to avoid its effect on different outcome parameters, as only minority of studied group was free from comorbidities. Another limitation comes from the small sample size; therefore, additional studies with higher number of patients are required to confirm findings of this study.
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